GEN Exclusives

More »

GEN News Highlights

More »
Jul 3, 2012

EC Clears Eisai’s Epilepsy Drug as Monotherapy

  • The EC approved expanded use of Eisai’s once-daily epilepsy drug Zonegran® (zonisaminde) to include monotherapy against partial seizures (with or without secondary generalization) in adults with newly diagnosed epilepsy. The drug had previously been approved as adjunctive therapy.

    Approval in Europe for the monotherapy indication was based on a trial in 583 newly diagnostic adult partial epilepsy patients that demonstrated the safety and noninferiority of once-daily zonisaminde compared with twice-daily controlled-release carbamazepine monotherapy in terms of seizure-free response rates at six months. “Zonegran is already a successful, once-daily add-on therapy for patients with epilepsy,” comments Bettina Bauer, head of EMEA epilepsy business unit at Eisai Eruope. “Zonegran is one of only six anti-epilepsy drugs available as monotherapy.”

    Also today Eisai confirmed that the EMEA has accepted for review its application for approval of Zonegran as an adjunctive therapy for pediatric patients aged six years and over with partial seizures. The firm is developing Zonegran in Europe under license from Dainippon Sumitomo Pharma. Sales of the drug in Europe were JPY 4.5 billion (about $60 million) in fiscal year 2011, up from JPY 4.3 billion in 2010. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?